Momenta Pharmaceuticals, Inc. (MNTA) COO Sells $75,936.78 in Stock

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) COO Ganesh Venkataraman Kaundinya sold 4,986 shares of the firm’s stock in a transaction that occurred on Wednesday, February 14th. The stock was sold at an average price of $15.23, for a total transaction of $75,936.78. Following the completion of the transaction, the chief operating officer now directly owns 501,031 shares in the company, valued at $7,630,702.13. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Ganesh Venkataraman Kaundinya also recently made the following trade(s):

  • On Monday, February 12th, Ganesh Venkataraman Kaundinya sold 341 shares of Momenta Pharmaceuticals stock. The stock was sold at an average price of $16.20, for a total transaction of $5,524.20.
  • On Thursday, February 8th, Ganesh Venkataraman Kaundinya sold 1,917 shares of Momenta Pharmaceuticals stock. The stock was sold at an average price of $16.00, for a total transaction of $30,672.00.
  • On Tuesday, November 21st, Ganesh Venkataraman Kaundinya sold 821 shares of Momenta Pharmaceuticals stock. The stock was sold at an average price of $13.15, for a total transaction of $10,796.15.

Momenta Pharmaceuticals, Inc. (MNTA) traded up $0.25 during mid-day trading on Wednesday, hitting $16.25. 934,334 shares of the stock traded hands, compared to its average volume of 927,496. The stock has a market cap of $1,245.11, a price-to-earnings ratio of -20.31 and a beta of 1.80. Momenta Pharmaceuticals, Inc. has a 1 year low of $11.85 and a 1 year high of $19.46.

A number of research analysts have weighed in on the stock. Stifel Nicolaus reissued a “hold” rating and issued a $18.00 target price on shares of Momenta Pharmaceuticals in a research note on Tuesday, January 30th. BidaskClub raised shares of Momenta Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday. Zacks Investment Research lowered shares of Momenta Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, December 4th. Finally, Cowen set a $15.00 target price on shares of Momenta Pharmaceuticals and gave the stock a “hold” rating in a research note on Wednesday, November 1st. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and one has issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $15.30.

Hedge funds have recently added to or reduced their stakes in the company. New York State Common Retirement Fund raised its position in shares of Momenta Pharmaceuticals by 9.4% during the 2nd quarter. New York State Common Retirement Fund now owns 286,453 shares of the biotechnology company’s stock valued at $4,841,000 after buying an additional 24,715 shares during the period. Principal Financial Group Inc. raised its position in shares of Momenta Pharmaceuticals by 12.0% during the 3rd quarter. Principal Financial Group Inc. now owns 606,700 shares of the biotechnology company’s stock valued at $11,224,000 after buying an additional 65,014 shares during the period. Los Angeles Capital Management & Equity Research Inc. purchased a new stake in shares of Momenta Pharmaceuticals during the 3rd quarter valued at approximately $1,141,000. Fisher Asset Management LLC purchased a new stake in shares of Momenta Pharmaceuticals during the 3rd quarter valued at approximately $1,823,000. Finally, Candriam Luxembourg S.C.A. raised its position in shares of Momenta Pharmaceuticals by 15.0% during the 3rd quarter. Candriam Luxembourg S.C.A. now owns 422,000 shares of the biotechnology company’s stock valued at $7,807,000 after buying an additional 55,000 shares during the period. 93.01% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “Momenta Pharmaceuticals, Inc. (MNTA) COO Sells $75,936.78 in Stock” was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this article on another site, it was illegally copied and republished in violation of United States & international copyright laws. The correct version of this article can be read at https://www.americanbankingnews.com/2018/02/14/momenta-pharmaceuticals-inc-mnta-coo-sells-75936-78-in-stock.html.

Momenta Pharmaceuticals Company Profile

Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).

Insider Buying and Selling by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply